AZD3409

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2013
02420042013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
AZD3409 is a novel DPTI that has potent activity against both FTase and GGTase-1. The in vitro inhibition profile of AZD3409 was… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
The kinetics of the HCl-catalyzed deprotection of the Boc-protected amine, thioester 2 to liberate AZD3409 1 have been studied in… (More)
Is this relevant?
2008
2008
The aim of the present investigation is to develop a simple, fast, and sensitive method for the determination of a new candidate… (More)
Is this relevant?
2008
2008
AZD3409 is an orally active double prodrug that was developed as a novel dual prenyltransferase inhibitor. The formation of the… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2006
2006
Mutations at the H-, N- and K-ras loci are among the most frequent genetic alterations in human cancers. In this study, we have… (More)
Is this relevant?
2006
2006
BACKGROUND The antineoplastic activity of AZD3409 was evaluated in relation to paclitaxel in human breast (MDA-MB-231, BT-474… (More)
  • table I
  • table II
  • figure 1
  • figure 2
Is this relevant?
2006
2006
AKT and MAPK signaling are involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. RAS… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2004
2004
4744 Background: Prostate cancer is the most common malignancy in men with a predilection to metastasize to the bone. There is a… (More)
Is this relevant?
2004
2004
3172 Background: AZD3409 is a novel, oral, antitumor agent that acts as a prenyl transferase inhibitor. It has potentially broad… (More)
Is this relevant?
2004
2004
3177 Background: AZD3409 is a novel, oral prenyl transferase inhibitor that has potential broad antitumor activity both as… (More)
Is this relevant?